Pfizer (PFE) Says Updated Data from Phase 3 Trial of IBRANCE Plus Letrozole in ER+, HER2- Metastatic Breast Cancer Confirm Improvement in PFS
Tweet Send to a Friend
Pfizer Inc. (NYSE: PFE) today announced updated progression-free survival (PFS) results from the Phase 3 PALOMA-2 trial reinforcing the clinical ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
